Meeting
2020 ASCO Virtual Scientific Program
Identification of pathogenic ROS1 alterations in cell-free DNA (cfDNA) from patients with breast cancer.
Authors
Jeremy Meyer Force
Duke University Medical Center, Durham, NC
Jeremy Meyer Force , Mary Love Taylor , Leylah Drusbosky , Jennifer Yen , Paul Kelly Marcom , Carey K. Anders , Jeffrey R Marks
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1031)
DOI
10.1200/JCO.2020.38.15_suppl.1031
Abstract #
1031
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.
First Author: Matthew P. Goetz
Poster
2023 ASCO Annual Meeting
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
First Author: Arielle J Medford
Poster
2020 ASCO Virtual Scientific Program
The landscape of genomic alterations detected in serial circulating tumor DNA (ctDNA) in clinical progressive metastatic breast cancer.
First Author: Saya Jacob
Poster
2020 ASCO Virtual Scientific Program
Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.
First Author: Huiping Li